Nanomedicine review: clinical developments in liposomal applications

Table 10 Toxicity of the clinical trials to paclitaxel

References	Disease	LF	Toxicity^a Grade 3–5 (%)
References	Disease	LF	N	A	T	L	Na	D	V	P	Ast
Wang and Zhang (2014)	NSCLC	L-PTX + carboplatin		13		57
Lu et al. (2015)	NSCLC	L-PTX + gemcitabine + carboplatin	14	4	2		2	4	2
Ahn et al. (2014)	NSCLC	Genexol-PM + gemcitabine	16					3			7
Ignatiadis et al. (2016)	BC	EndoTAG-1 + paclitaxel + fluorouracil + epirubicin + cyclophosphamide	7
Awada et al. (2014)	TNBC	EndoTAG-1 + paclitaxel	22	2		7			2	2	6
Awada et al. (2014)	TNBC	EndoTAG-1	5			2		2		4	5
Lu et al. (2016)	AGC	L-PTX + capecitabine		2.9		17.6
Xu et al. (2013)	MGC	Lipusu^®		3		7	3		3
Haas et al. (2012)	APC	EndoTAG-1 + gemcitabine	12		8	10			2
			16	4	16	12				6
			22	8	14	10	6		4	8
Graziani et al. (2017)^b	EOC	PTX–LCN
Strieth et al. (2013)^c	HNC	EndoTAG-1
Slingerland et al. (2017)^d	AC	LEP-ETU	17			3

In the blanks, this type of toxicity is not reported
LF liposomal formulation, n number of patients, LPTX liposomal paclitaxel, PTX–LCN paclitaxel lipid core nanoparticle, PTX paclitaxel, Gem gemcitabine, LEP-ETU paclitaxel liposomal, BC breast cancer, TNBC triple-negative breast cancer, AGC atypical glandular cells, MGC metastatic gastric cancer, PC pancreatic cancer, EOC epithelial ovarian carcinoma, HNC head and neck cancer, AC advance cancer, NSCLC non-small-cell lung carcinoma, N neutropenia, A anemia, T thrombocytopenia, L leukopenia, Na nauseas, D diarrhea, V vomiting, P pneumonia, Ast asthenia
^aToxicity was rounded
^bNo grade > 3 even grade < 2 toxicity was found
^cNo grade > 3 toxicity or severe adverse events occurred
^dNo results have been proportionated